IP Library Granted Patent US 8,445,272
Granted Patent B2
US 8,445,272 · App. 13/196,631 · Granted May 21, 2013

Method of stimulating NKT with 6″-amino-6″-deoxygalactosylceramides

Inventors: Paul B. Savage (Mapleton, UT); Albert Bendelac (Chicago, IL); Luc Teyton (Delmar, CA)
Assignees: The Scripps Research Institute; The University of Chicago; Brigham Young University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,272
App. No.
13/196,631
Granted
May 21, 2013
Kind
B2
Abstract

This invention relates to galactosylceramide compounds.

Claims (30)

1. A method of stimulating NKT cells comprising contacting an NKT cell with a compound of Formula (I) and a CD1 protein, wherein the compound of Formula (I) comprises:

wherein,

R 1 is —C(O)R 10 , wherein R 10 is C 1 -C 12 alkyl optionally substituted with carboxyl;

R 2 is hydrogen;

R 3 , R 4 , R 5 , R 6 and R 7 are each hydrogen;

R 8 is —(CH 2 ) x CH 3 ;

R 9 is a linear or branched C 3 -C 100 alkyl; and

x is 1-100.

2. An isolated antigen presenting cell for presenting a lipid antigen to NKT cells, the antigen presenting cell comprising CD1d molecules loaded with a compound of Formula (I), the compound of Formula (I) comprising:

wherein,

R 1 is —C(O)R 10 , wherein R 10 is C 1 -C 12 alkyl optionally substituted with carboxyl;

R 2 is hydrogen;

R 3 , R 4 , R 5 , R 6 and R 7 are each hydrogen;

R 8 is —(CH 2 ) x CH 3 ;

R 9 is a linear or branched C 3 -C 100 alkyl; and

x is 1-100.

3. The isolated antigen presenting cell of claim 2 , wherein x is 24 and R 9 is n-tetradecyl.

4. The isolated antigen presenting cell of claim 2 , wherein R 10 is CH 3 .

5. The isolated antigen presenting cell of claim 4 , wherein R 9 is C 14 alkyl.

6. The isolated antigen presenting cell of claim 5 , wherein R 8 is —(CH 2 ) 24 CH 3 .

7. The isolated antigen presenting cell of claim 5 , wherein R 8 is —(CH 2 ) 22 CH 3 .

8. The isolated antigen presenting cell of claim 2 , wherein R 10 is selected from —(CH 2 ) 2 COOH, —(CH 2 ) 3 COOH, and —(CH 2 ) 4 COOH.

9. A method of stimulating an NKT cell, comprising contacting the NKT cell with an antigen presenting cell according to claim 2 .

10. The method of claim 1 , wherein contacting comprises contacting the NKT cell with an antigen presenting cell comprising CD1d molecules loaded with the compound of Formula (I).

11. The method of claim 1 , wherein x is 24 and R 9 is n-tetradecyl.

12. The method of claim 1 , wherein R 10 is CH 3 .

13. The method of claim 12 , wherein R 9 is C 14 alkyl.

14. The method of claim 13 , wherein R 8 is —(CH 2 ) 24 CH 3 .

15. The method of claim 13 , wherein R 8 is —(CH 2 ) 22 CH 3 .

16. The method of claim 1 , wherein R 10 is selected from —(CH 2 ) 2 COOH, —(CH 2 ) 3 COOH, and —(CH 2 ) 4 COOH.

Assignments (1)
CONFIRMATORY LICENSE Recorded Apr 18, 2017
From: BRIGHAM YOUNG UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 042276/0283 →
Continuity (3)
Continuation 12625048 · Nov 24, 2009
Division 10550165
Related Publication 20120028915A1 · Feb 2, 2012